{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T23:26:32Z","timestamp":1782775592406,"version":"3.54.5"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T00:00:00Z","timestamp":1576108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s40273-019-00862-w","type":"journal-article","created":{"date-parts":[[2019,12,12]],"date-time":"2019-12-12T02:48:59Z","timestamp":1576118939000},"page":"307-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome"],"prefix":"10.1007","volume":"38","author":[{"given":"Michael","family":"Ryan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie M. K.","family":"Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Irish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Gasteyger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"L\u2019Italien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Laurence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,12]]},"reference":[{"issue":"2","key":"862_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.chest.2017.03.055","volume":"152","author":"E Azoulay","year":"2017","unstructured":"Azoulay E, et al. Expert statements on the standard of care in critically ill adult patients with atypical hemolytic uremic syndrome. Chest. 2017;152(2):424\u201334.","journal-title":"Chest."},{"issue":"10095","key":"862_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681\u201396.","journal-title":"Lancet."},{"key":"862_CR3","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844\u201359.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"4","key":"862_CR4","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554\u201362.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"11","key":"862_CR5","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1038\/nbt1344","volume":"25","author":"RP Rother","year":"2007","unstructured":"Rother RP, Rollins SA, Mojcik CF, Brodsky RA, Bell L. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Nat Biotechnol. 2007;25(11):1256\u201364.","journal-title":"Nat Biotechnol."},{"issue":"1","key":"862_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.kint.2019.01.009","volume":"96","author":"Y Ueda","year":"2019","unstructured":"Ueda Y, et al. Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation. Kidney Int. 2019;96(1):67\u201379.","journal-title":"Kidney Int."},{"issue":"23","key":"862_CR7","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169\u201381.","journal-title":"N Engl J Med."},{"issue":"5","key":"862_CR8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87(5):1061\u201373.","journal-title":"Kidney Int."},{"issue":"1","key":"862_CR9","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40620-016-0288-3","volume":"30","author":"J Vande Walle","year":"2017","unstructured":"Vande Walle J, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol. 2017;30(1):127\u201334.","journal-title":"J Nephrol."},{"issue":"10, S15","key":"862_CR10","first-page":"4","volume":"11","author":"J Laurence","year":"2013","unstructured":"Laurence J. Atypical hemolytic uremic syndrome (aHUS): treating the patient. Clinical Adv Hematol Oncol. 2013;11(10, S15):4\u201315.","journal-title":"Clinical Adv Hematol Oncol."},{"key":"862_CR11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/trf.13359","volume":"56","author":"NT Connell","year":"2016","unstructured":"Connell NT, Cheves T, Sweeney JD. Effect of ADAMTS13 activity turnaround time on plasma utilization for suspect thrombotic thrombocytopenic purpura. Transfusion. 2016;56:354\u20139.","journal-title":"Transfusion."},{"issue":"Suppl 11","key":"862_CR12","first-page":"2","volume":"14","author":"J Laurence","year":"2016","unstructured":"Laurence J, Haller H, Mannucci PM, Nangaku M, Praga M, Rodriguez de Cordoba S. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol. 2016;14(Suppl 11):2\u201315.","journal-title":"Clin Adv Hematol Oncol."},{"key":"862_CR13","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrneph.2012.214","volume":"8","author":"J Zuber","year":"2012","unstructured":"Zuber J, et al. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643\u201357.","journal-title":"Nat Rev Nephrol"},{"key":"862_CR14","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ekir.2018.11.010","volume":"4","author":"AM Siedlecki","year":"2019","unstructured":"Siedlecki AM, et al. Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney Int Rep. 2019;4:434\u201346.","journal-title":"Kidney Int Rep"},{"key":"862_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","volume":"36","author":"A Elixhauser","year":"1998","unstructured":"Elixhauser A, et al. Comorbidity measures for use with administrative data. Med Care. 1998;36:8\u201327.","journal-title":"Med Care."},{"issue":"12","key":"862_CR16","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1111\/j.1600-6143.2012.04252.x","volume":"12","author":"J Zuber","year":"2012","unstructured":"Zuber J, et al. Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation. Am J Transplant. 2012;12(12):3337\u201354.","journal-title":"Am J Transplant."},{"key":"862_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfz066","author":"U Sch\u00f6nermarck","year":"2019","unstructured":"Sch\u00f6nermarck U, et al. Relative incidence of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in clinically suspected cases of thrombotic microangiopathy. Clin Kidney J. 2019. https:\/\/doi.org\/10.1093\/ckj\/sfz066.","journal-title":"Clin Kidney J."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00862-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-019-00862-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-019-00862-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:28:23Z","timestamp":1607646503000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-019-00862-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,12]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["862"],"URL":"https:\/\/doi.org\/10.1007\/s40273-019-00862-w","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,12]]},"assertion":[{"value":"12 December 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Alexion Pharmaceuticals, Inc. (study funder). Study design was undertaken by Bonnie M.K. Donato and Gilbert\u00a0L\u2019Italien (former employees of study funder). Study conduct was overseen by Michael Ryan and William Irish (contracted by study funder). Data analysis and interpretation was undertaken by Christoph Gasteyger (employee of study funder) and Jeffrey Laurence (a consultant to the study funder). The first draft of the manuscript was developed by the medical writer (contracted by the study funder) under guidance from the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Michael Ryan is an employee of CTI, a paid consultant of Alexion. Bonnie M.K. Donato is an employee of Boehringer-Ingelheim Pharmaceutical Inc. and was an employee of Alexion Pharmaceuticals, Inc. at the time of the study. William Irish has no disclosures to declare. Christoph Gasteyger is an employee of Alexion Pharma GmbH. Gilbert\u00a0L\u2019Italien is a former employee of Alexion Pharmaceuticals, Inc. Jeffrey Laurence is a consultant to Alexion.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study has been approved by the appropriate institutional and\/or national research ethics committee and has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human rights"}}]}}